Type of Study: Clinical Trial

Sponsor / Support: LACOG

Primary Objectives: The primary objective is to evaluate if pembrolizumab improves Overall Response Rate in first-line setting associated with platinum-based chemotherapy.

Design: This is a phase II, multicenter, open-label, one-arm interventional trial. 

Sample Size: 33 patients

Principal Investigator: Fernando Cotait Maluf

Countries LATAM: Brazil